- Home
- NBTX vs PYXS Comparison
NBTX vs PYXS Comparison
Compare NBTX & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- PYXS
- Stock Information
- Founded
- NBTX 2003
- PYXS 2018
- Country
- NBTX France
- PYXS United States
- Employees
- NBTX N/A
- PYXS N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- NBTX Health Care
- PYXS Health Care
- Exchange
- NBTX Nasdaq
- PYXS Nasdaq
- Market Cap
- NBTX 201.9M
- PYXS 210.4M
- IPO Year
- NBTX 2020
- PYXS 2021
- Fundamental
- Price
- NBTX $4.00
- PYXS $4.72
- Analyst Decision
- NBTX Strong Buy
- PYXS Strong Buy
- Analyst Count
- NBTX 2
- PYXS 7
- Target Price
- NBTX $11.50
- PYXS $9.57
- AVG Volume (30 Days)
- NBTX 6.4K
- PYXS 660.4K
- Earning Date
- NBTX 11-19-2024
- PYXS 11-15-2024
- Dividend Yield
- NBTX N/A
- PYXS N/A
- EPS Growth
- NBTX N/A
- PYXS N/A
- EPS
- NBTX N/A
- PYXS N/A
- Revenue
- NBTX $45,220,186.00
- PYXS $16,146,000.00
- Revenue This Year
- NBTX N/A
- PYXS N/A
- Revenue Next Year
- NBTX N/A
- PYXS N/A
- P/E Ratio
- NBTX N/A
- PYXS N/A
- Revenue Growth
- NBTX 526.17
- PYXS N/A
- 52 Week Low
- NBTX $4.04
- PYXS $1.35
- 52 Week High
- NBTX $8.96
- PYXS $6.85
- Technical
- Relative Strength Index (RSI)
- NBTX 37.42
- PYXS 74.43
- Support Level
- NBTX $4.07
- PYXS $3.88
- Resistance Level
- NBTX $4.44
- PYXS $5.39
- Average True Range (ATR)
- NBTX 0.21
- PYXS 0.27
- MACD
- NBTX -0.03
- PYXS 0.11
- Stochastic Oscillator
- NBTX 0.00
- PYXS 64.48
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.